trofosfamide has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bela, C; Engels, C; Klink, T; Stölting, S; Wagner, T | 1 |
| Egerer, G; Ho, AD; Kasper, B | 1 |
2 other study(ies) available for trofosfamide and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Administration Schedule; Humans; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
A new therapeutic approach in patients with advanced sarcoma.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Female; Humans; Lactones; Male; Middle Aged; Neovascularization, Pathologic; Palliative Care; Pilot Projects; Pioglitazone; Sarcoma; Soft Tissue Neoplasms; Sulfones; Thiazolidinediones; Treatment Outcome | 2005 |